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R.L. Juliano, Xin Ming, Kyle Carver, and Brian Laing
One of the major constraints on the therapeutic use of oligonucleotides is inefficient delivery to their sites of
action in the cytosol or nucleus. Recently it has become evident that the pathways of cellular uptake and
intracellular trafficking of oligonucleotides can strongly influence their pharmacological actions. Here we pro-
vide background information on the basic processes of endocytosis and trafficking and then review recent
literature on targeted delivery and subcellular trafficking of oligonucleotides in that context. A variety of ap-
proaches including molecular scale ligand-oligonucleotide conjugates, ligand-targeted nanocarriers, and the use
of small molecules to enhance oligonucleotide effects are discussed.
Introduction
The delivery of antisense and small interfering RNA(siRNA) oligonucleotides to their intracellular sites of
action within tissues remains a major challenge for the oli-
gonucleotide therapeutics field (Burnett and Rossi, 2012; Kole
et al., 2012). Recent research has made it clear that the
mechanisms of cellular uptake and subcellular trafficking of
oligonucleotides play key roles in determining their biological
effects (Varkouhi et al., 2011; Juliano et al., 2012a). Thus, this
article will briefly examine basic aspects of endocytosis and
intracellular trafficking and will then discuss studies con-
necting these processes to oligonucleotide pharmacology and
therapy. In particular, we will examine the merits of certain
receptor families and their trafficking pathways as targets for
enhanced oligonucleotide delivery. We will also discuss the
uptake and pharmacological effects of various receptor-
targeted oligonucleotide conjugates or nanocomplexes. Much
of the review will focus on cell-based studies, since mean-
ingful investigations on oligonucleotide trafficking in vivo are
rare; however, a few interesting examples will be mentioned.
This review will examine studies with splice switching oli-
gonucleotides (SSOs) as well as antisense (AS) and siRNA
oligonucleotides.
Basic Essentials of Endocytosis and Trafficking
Both single and double stranded oligonucleotides usually
enter cells by one of several endocytotic pathways (Doherty
and McMahon, 2009; Howes et al., 2010; Varkouhi et al., 2011;
Juliano et al., 2012a). Uptake via clathrin-coated pits is the
archetypal and best-studied route and many adaptor and
accessory proteins for this pathway have been identified, for
example, the key adapter protein AP-2. After pinching off of
the coated vesicle by a dynamin mediated mechanism (Met-
tlen et al., 2009), the vesicle is uncoated under the influence of
auxilin and heat shock protein 70 and is ready to begin its
intracellular journey. Many physiologically significant mac-
romolecules such as low-density lipoproteins and transferrin
enter cells via the clathrin pathway and may be used as
markers for this route. The caveolar pathway, involving rel-
atively small lipid rich vesicles ( < 100 nanometers as com-
pared to sub-micron sizes for other pathways) marked by
hydrophobic hairpin proteins termed caveolins, has also eli-
cited a great deal of interest (Lajoie and Nabi, 2010). Notably,
the cytosolic faces of caveolae are decorated with many pro-
teins involved in signal transduction (Sorkin and von Zas-
trow, 2009); however, the magnitude of the caveolar
contribution to the internalization of large molecules is un-
clear. Cholera toxin is a widely used but imperfect marker for
uptake via caveolae.
There are also several non-clathrin non-caveolin dependent
routes of endocytosis that are garnering increased attention.
For example, one pathway gives rise to high volume tube
shaped endosomes that are enriched in glycerophos-
phatidylinositol (GPI)-proteins (such as the folate receptor,
FRa) and that are thought to be particularly important for
fluid-phase endocytosis. The acronym for this pathway is the
clathrin and dynamin independent carriers/GPI-AP enriched
early endosomal compartments pathway (Howes et al., 2010).
This route can be marked using high molecular weight
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dextrans or other neutral polymers. Macropinocytosis de-
scribes a process whereby actinomyosin-driven cell protru-
sions pinch off large volumes of extracellular fluid that are
then internalized in large vesicles; thus, this also represents an
important route for fluid phase endocytosis (Kerr and Teas-
dale, 2009). There are several additional clathrin and caveolin
independent pathways, but in most cases the mechanisms
involved are only beginning to be delineated (Howes et al.,
2010). Thus, in summary, we are currently aware of multiple
pathways for endocytosis with more probably remaining to
be discovered. This creates complexities but also opportuni-
ties for oligonucleotide pharmacology. For example, by using
ligands that target antisense or siRNA to specific cell surface
receptors, one can influence the initial route of internalization.
This may have important implications for subsequent intra-
cellular distribution and for the ultimate pharmacological
effect of the oligonucleotide (Alam et al., 2010).
Initial uptake of oligonucleotide is followed by intracellular
trafficking into a variety of endomembrane vesicular com-
partments including early/sorting endosomes, late endo-
somes/multivesicular bodies, lysosomes, and the Golgi
complex (see Fig. 1). If a receptor was involved in the initial
uptake, the receptor and its ligand are usually dissociated and
the receptor can often recycle back to the cell surface (Ha-
nyaloglu and von Zastrow, 2008; Xu et al., 2013). Intracellular
trafficking is an extremely dynamic process that is regulated
by a plethora of proteins and lipids that control the size,
content and ultimate destination of vesicle membrane and
contents. In the typical pathway of endocytosis, maturation of
vesicles from early to late endosomes and thence to lysosomes
is accompanied by dramatic changes in the protein and lipid
composition of the endosome as well as by progressive re-
duction in pH (Pfeffer, 2007; Huotari and Helenius, 2011).
Trafficking often involves a dynamic flux of small shuttle
vesicles between larger endomembrane compartments
(Spang, 2009; Hughson and Reinisch, 2010). During vesicular
budding and fusion events, discontinuities in the lipid bilayer
may occur thus potentially allowing for partial escape of
vesicle contents (Deamer and Bramhall, 1986; de Gier, 1993;
Gurtovenko et al., 2010); this ‘‘leakage’’ to the cytosol may be
an important facet of oligonucleotide pharmacology.
A variety of individual proteins or multiprotein complexes
are involved in the regulation of intracellular trafficking.
Many aspects of trafficking are controlled by members of the
large Rab family of GTPases (Stenmark, 2009; Hutagalung
and Novick, 2011); this includes vesicle coating or uncoat-
ing processes, linkages to the cytoskeleton for movement of
vesicles, and membrane recognition and fusion events. In-
dividual Rabs also serve as markers for particular compart-
ments (Pfeffer, 2013); for example, Rab5 is characteristic of
early/recycling endosomes, while Rab 7 demarcates late en-
dosomes. The specific docking of different types of vesicles to
each other involves multiprotein tethering complexes for
recognition, while vesicular fusion events are controlled by
soluble Nsf attachment protein receptor proteins that can
cause membrane destabilization (Cai et al., 2007). Trafficking
via late endosomes/multivesicular bodies to lysosomes is
regulated by the multicomponent endosomal sorting com-
plexes required for transport (Henne et al., 2011), which also
contributes to the formation of exosomes that are released
externally and can traffic between cells (Bobrie et al., 2011).
The atypical retrograde trafficking pathway (Johannes and
Wunder, 2011) that conveys materials from early endosomes to
the Golgi rather than to lysosomes involves the retromer
complex and its associated sorting nexins. Trafficking via
this pathway can protect vesicle contents from lysosome-
mediated degradation. Ubiquitin and its recognition proteins
also play a key role in trafficking particularly for endosome
components destined for proteolytic degradation for (Clague
et al., 2012). Note that the multiplicity of proteins involved in
intracellular trafficking could provide many opportunities to
modulate these processes, possibly in ways that would en-
hance oligonucleotide effectiveness.
In summary, intracellular trafficking involves an extremely
dynamic and highly orchestrated set of processes that deliver
both membrane components and vesicular contents to their
appropriate places within the cell. It is clear that altering the
subcellular trafficking of molecules can have significant
FIG. 1. Routes of endocyto-
sis and trafficking. This de-
picts several of the common








in intracellular trafficking are
also shown. Key proteins in-
cluding clathrin, caveolin, dy-
namin, and various Rab
GTPases are shown. Color
images available online at
www.liebertpub.com/nat
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therapeutic implications (Mossalam et al., 2010). Because of
the complexity of intracellular traffic, its manipulation pres-
ents many challenges, but this complexity also offers many
opportunities to intervene. Recently there has been much in-
terest in the trafficking of oligonucleotides because of the
potential pharmacological importance (Overhoff and Sczakiel
2005; Alam et al., 2008; Kortylewski et al., 2009; Alam et al.,
2010; Ming et al., 2010; Koller et al., 2011; Ming et al., 2011;
Varkouhi et al., 2011; Juliano et al., 2012a); we will discuss
some of the key findings in more detail below.
Enhancing Receptor-Mediated Endocytosis
of Oligonucleotides: Opportunities and Limitations
A tried and true method for enhancing cellular uptake of
oligonucleotides is to link the nucleic acid to a ligand that
binds with high affinity to a cell surface receptor. This tactic
has been used for both molecular-scale, covalent ligand–oli-
gonucleotide conjugates (Deleavey et al., 2009; Juliano et al.,
2012b) and for oligonucleotides complexed with nanoscale
lipid- or polymer-based carriers (Li et al., 2013; Xu et al., 2013).
Ideally this approach can provide both increased uptake and
improved selectivity, particularly if the receptor chosen is
differentially expressed on a specific cell type. In designing
approaches for receptor-mediated delivery of oligonucleo-
tides it is vital to be aware of the basic biology of the receptor
involved. Here we will briefly outline some of the key char-
acteristics of three major receptor families that have been used
in the delivery of nucleic acids (see Fig. 2).
The integrin family
Integrins are heterodimeric cell surface proteins that are
involved in cell-extracellular matrix (ECM) adhesion, orga-
nization of the cytoskeleton, and various signaling processes
(Hynes, 2002; Schwartz, 2010). The integrin family in mam-
mals includes 18 alpha subunits and 8 beta subunits giving
rise to 24 individual heterodimers (Margadant et al., 2011).
Integrins ordinarily bind to large ECM proteins such as fi-
bronectin and collagen, but the discovery that the short pep-
tide arg-gly-asp (RGD) could bind to certain integrins
(Pierschbacher and Ruoslahti, 1984) led to the development of
many small molecule ligands for this receptor family. The
cytoplasmic tails of integrins associate with proteins such as
talin, filamin, and kindlin that then provide a mechano-
chemical linkage to the actin cytoskeleton.
In addition to their role in cell adhesion and cytoskeletal
organization, integrins also participate in signal transduction.
This has been divided into ‘‘inside out’’ and ‘‘outside in’’
signaling. Inside out signaling refers to the fact that an in-
tegrin can exist in different affinity states for its ECM ligands
(Kim et al., 2011). These states correlate with the overall shape
of the integrin and the spacing of the cytoplasmic a and b tails
and are regulated by the binding of talin to the b tail. Outside
in signaling refers to the fact that integrin engagement with
ligand can both directly trigger signaling processes and also
modulate signaling through other receptor systems (Streuli
and Akhtar, 2009). The best example of the former is integrin-
mediated activation of focal adhesion kinase, a cytosolic ty-
rosine kinase that can trigger a multiplicity of downstream
signaling events (Parsons, 2003). An example of the latter is
integrin-mediated enhancement of the mitogenic Erk/mito-
gen-activated protein (MAP) kinase pathway that lies
downstream from receptor tyrosine kinases (RTKs) ( Juliano
et al., 2004). Integrin engagement modulates activation of the
Erk kinase (Edin and Juliano, 2005) as well as its entry into the
nucleus (Aplin et al., 2001).
It is well known that integrins are internalized and then
usually recycle to the cell surface (Bretscher, 1992; Sczekan
and Juliano, 1990; Caswell et al., 2009), although in some cases
they may be ubiquitinated and degraded in lysosomes.
FIG. 2. Endocytosis and trafficking of receptors. The left panel illustrates the a5b1 integrin being internalized via a caveolar
pathway to Rab 5 positive early endosomes and then returning to the cell surface via Rab 11 positive recycling vesicles. The
middle panel illustrates epidermal growth factor receptor (EGFR) being internalized in clathrin coated vesicles, entering Rab 5
positive early endsomes, and then, due to previous ubiquitination, being destined for Rab 7 positive late endosomes and then
lysosomes where the receptor is degraded. The right panel illustrates a G protein-coupled receptors (GPCR) being internalized in
clathrin coated vesicles with the involvement of beta-arrestin and then returning from early endosomes to the cell surface via
Rab 4 positive recycling vesicles. A portion of the GPCR may also traffic to lysosomes. The fate of the ligand is not illustrated in
these diagrams. Color images available online at www.liebertpub.com/nat
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Similar to the situation in signaling, there are interesting re-
ciprocal effects on recycling between integrins and other re-
ceptors, especially the RTKs (Caswell et al., 2008; Wickstrom
and Fassler, 2011). Internalization of certain integrins via
clathrin-coated pits is thought to play an important role in
focal adhesion disassembly. However, some integrins are in-
ternalized by clathrin-independent mechanisms; thus, avb3
and a5b1 have been reported to internalize via caveolae
(Karjalainen et al., 2008). After internalization and entry into
Rab5 positive early endosomes, integrins can recycle to the
cell surface via a Rab4 positive ‘‘short-loop’’ pathway (e.g.,
avb3) or via the Rab11 positive perinuclear recycling com-
partment (e.g., a5b1) (Caswell et al., 2009).
Because they are structural as well as signaling proteins,
integrins are usually expressed at quite high levels compared
to other receptors, often at 105 copies per cell or more (Mul-
grew et al., 2006; Szabo et al., 2012). This is one reason why
integrins are attractive for designing delivery approaches.
Even more importantly, although most cells express several
members of the integrin family, in a number of cases there is
strong differential expression of a particular integrin. The
most extreme example is aIIbb3 that is exclusively expressed
in platelets or their precursors. Another example of wide in-
terest is avb3, which is highly expressed in angiogenic vas-
culature and in certain types of tumors (Desgrosellier and
Cheresh, 2010). Thus, various versions of cyclic RGDs that
preferentially bind to avb3 have been pursued for delivery of
nucleic acids as well as conventional drugs and imaging
agents (Niu and Chen, 2011).
Broad interest in therapeutic possibilities involving in-
tegrins has led to the development of a variety of highly se-
lective integrin ligands as well as information on how the
ligands affect integrin structure and function (Shimaoka and
Springer, 2003). Thus, a number of small molecule ligands
exist for aIIbb3, avb3, and a4b1, and the aIIbb3 drugs have
found a role in the clinic in preventing thrombotic problems
(Millard et al., 2011). Synthetic integrin ligands usually bind
in the cleft between the a and b subunits, and virtually all are
competitive inhibitors of the physiological ligands. Thus,
another advantage of utilizing integrins for delivery strategies
is the ready availability of a number of very selective, high
affinity ligands.
In summary, integrins have some attractive features for
selective delivery of oligonucleotides. They are often ex-
pressed at relatively high levels, they efficiently recycle to the
cell surface, and high affinity ligands are available, at least for
some integrins. Potential liabilities include the fact that some
integrins are very broadly expressed (e.g., a5b1, a fibronectin
receptor), while high affinity ligands are not available for all
members of the family.
The G protein-coupled receptor superfamily
Numbering several hundred, the G protein-coupled re-
ceptors (GPCRs) comprise the largest receptor family and its
members play roles in a multiplicity of physiological func-
tions (Armbruster and Roth, 2005). GPCRs vary greatly in
primary sequence but share a common topology based on
seven transmembrane helices. The classic mechanism of
GPCR signaling involves a ligand activated conformational
change in the receptor that alters its association with its
bound heterotrimeric G protein partner, resulting in the ex-
change of GDP for GTP on the G protein a subunit and re-
lease of both the Ga subunit and the bg subunit complex
from the receptor (Cabrera-Vera et al., 2003). The G protein
subunits can then interact with a variety of downstream ef-
fectors (Gilman, 1995). For various G protein subtypes, the
effectors would include adenylate cyclase, phospholipase
Cb, and various ion channels. The GTP loading and activity
of the Ga subunit is negatively regulated by members of
the regulators of G-protein signaling protein family (Kimple
et al., 2011), thus restoring the inactive state.
GPCR signaling events are highly connected with the in-
ternalization and intracellular trafficking of the receptor
(Drake et al., 2006; Hanyaloglu and von Zastrow, 2008). In-
ternalization includes a process that de-sensitizes the receptor
and reduces signaling via ‘‘classic’’ second messengers like
cyclic AMP but can also include the recruitment of new sig-
naling moieties with different downstream effects. Receptor
internalization involves phosphorylation of the cytosolic tail
by members of a family of GPCR kinases. This triggers the
recruitment of the key adaptor protein b-arrestin that can then
interact with the AP-2 protein allowing recruitment of the
GPCR into clathrin-coated pits and endocytotic vesicles. The
formation of a GPCR/arrestin complex on the cytoplasmic
face of the endosome results in the formation a new G Protein-
independent signaling complex that can recruit the c-Src
tyrosine kinase as well as other proteins and project into mi-
togenic signaling pathways (Shukla et al., 2011). Thus, GPCRs
have dual signaling mechanisms depending on their locali-
zation within the cell.
Internalization of activated, agonist bound GPCRs is pri-
marily via the clathrin dependent pathway; however, certain
GPCRs have been observed in association with lipid rafts or
caveolae. In most instances, the internalization of GPCRs that
are not liganded with an agonist is much more limited. After
trafficking to Rab5 positive early endosomes GPCRs can un-
dergo two distinct fates. One involves sorting to multi-
vesicular bodies and thence to lysosomes for degradation,
while the other involves returning to the cell surface via Rab4
or Rab11 positive recycling compartments (Hanyaloglu and
von Zastrow, 2008).
GPCRs often display strong differential expression in var-
ious tissues or in disease states. One situation is the over-
expression of certain GPCRs in various cancers (Li et al., 2005).
For example, the gastrin releasing peptide receptor GRPR has
been implicated in a number of carcinomas (Cornelio et al.,
2007) and radiolabeled GRPR ligands have been successfully
used for tumor imaging (Garrison et al., 2007). More directly
to the point here, we have used a peptide ligand for GRPR to
deliver oligonucleotides to GRPR-positive prostate tumor
cells (Ming et al., 2010). One potential problem with utiliza-
tion of GPCRs for delivery purposes is their relatively low
abundance (Post et al., 1995; Houston et al., 2006). While ex-
pression levels differ dramatically between different GPCRs
and in different tissue settings, in general they are lower than,
for example, integrins. As a rather broad generalization,
GPCRs are often expressed at 103 to 104 copies per cell (Le-
vitzki et al., 1974).
Molecules that act on GPCRs comprise approximately 40%
of all clinically utilized drugs while GPCRs may account for
28% of the ‘‘druggable genome’’ (Hopkins and Groom, 2002;
Filmore, 2004). Thus there exists a huge armamentarium of
GPCR ligands, some of which have made it to the clinic, while
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many more have been abandoned and now lurk in chemical
catalogs or in the storehouses of pharmaceutical companies.
This provides the opportunity for development of a large
variety of ligand–oligonucleotide conjugates or liganded oli-
gonucleotide nanocarriers designed to enhance delivery via
GPCR mediated endocytosis.
Thus with GPCRs there is a mixed picture in terms of de-
livery. High affinity ligands are often available for various
individual GPCRs. However, these receptors are not as highly
expressed as members of some other receptor families are.
Additionally, the receptor recycling process is incomplete and
a substantial fraction of receptor can be delivered to lyso-
somes and degraded, thus eventually reducing receptor ex-
pression on the cell surface.
The receptor tyrosine kinases
Members of this large family of receptors play key roles in
mitogenesis and cell growth control and are activated by
polypeptide ligands. Binding of the ligand to the RTK leads to
receptor dimerization, autophosphorylation of the cytosolic
domain, and tyrosine phosphorylation of bound partner
proteins. This leads to the creation of multiprotein signal
transduction hubs that can branch to activate several down-
stream pathways (Hynes and Lane, 2005; Lemmon and
Schlessinger, 2010; Koch and Claesson-Welsh, 2012). A typical
example of this is stimulation of the epidermal growth factor
(EGF) receptor leading to activation of the Erk/MAP kinase
mitogenic pathway as well as the AKT survival pathway.
The intracellular trafficking of RTKs is tightly linked to
their functions (Parachoniak and Park, 2012). The epidermal
growth factor receptor (EGFR) is one of the best-studied RTKs
and can serve as an example. Thus the cytosolic tail of acti-
vated EGFR interacts with adapter proteins including AP-2 to
cluster the receptor in clathrin-coated pits. After dynamin
mediated scission of the coated vesicles from the membrane
and release of the clathrin coat, the EGFR enters early endo-
somes and is then trafficked to late endosomes/multivesicular
bodies and thence to lysosomes, where both the receptor and
its ligand are degraded thus resulting in termination of sig-
naling (Lemmon and Schlessinger, 2010). Interestingly, in-
ternalization of EGFR is required for signaling to one of its
downstream pathways, the AKT kinase pro-survival path-
way, but not for signaling to the Erk/MAP kinase pathway
(Goh et al., 2010). Other instances of interplay between sig-
naling and trafficking pathways of RTKs are also known
(Miaczynska and Bar-Sagi, 2010). In comparison to integrins,
RTKs tend to recycle to a lesser degree and are more likely to
traffic to the lysosome for degradation; however, there are
many variations for different members of the RTK family.
Differential expression of RTKs is found in a number of
disease states, particularly cancer. For example, the over-
expression of HER2 in certain forms of breast cancer is well
known (Shepard et al., 2008). Another instance involves
members of the Trk family of RTKs that are primarily ex-
pressed in neuronal or neuroepithelial tissues and that may
have a role in neuroblastoma (Brodeur et al., 2009). The
number of RTKs per cell can vary over a wide range. Thus, in
one study the EGFR was present in various cell lines in
amounts ranging from 103 to 106 copies per cell while in an-
other study the VEGFR2 was present at about 0.5–1.0 · 105
copies per vascular endothelial cell (Imai et al., 1982; Napione
et al., 2012). Thus RTKs can be expressed at levels of thou-
sands to hundreds of thousands of copies per cell; this is
potentially a useful range in terms of utilizing RTKs for tar-
geted delivery.
The physiological ligands for RTKs are all relatively large
polypeptides and thus present problems in terms of their use
in selective delivery. There are a variety of high affinity
monoclonal reagents for the external domains of RTKs (Hynes
and Lane, 2005; Krause and Van Etten, 2005). These can be
used themselves as targeting reagents, converted to Fab
fragments, or reconfigured as scFv reagents (Tohidkia et al.,
2012). There are a number of examples of delivery of drugs,
imaging agents, or nucleic acids with targeted nanoparticles
using approaches involving antibodies to RTKs (Kirpotin
et al., 2006; Liu et al., 2011; Hwang et al., 2012). However,
because of the size and complexity of RTK ligands, opportu-
nities for direct conjugation with oligonucleotides are limited.
As with the integrins, RTKs are often expressed at quite
high levels and thus may be useful for targeted delivery of
oligonucleotides. RTKs are primarily internalized via the
‘‘classic’’ clathrin pit pathway, enter low pH endosomal
compartments, and ultimately traffic to lysosomes. Thus,
RTKs may provide an effective means of delivery to these
compartments; this may be augmented by using pH sensitive
linkers. However, in contrast to some integrins that rapidly
recycle, the cell surface display of RTKs must be restored by
synthesis of new molecules. Therefore, strategies that involve
multiple dosing may not be appropriate if RTKs are used for
targeted delivery.
Perspective on receptor targeting
In the preceding paragraphs we have discussed some of the
characteristics of integrins, GPCRs and RTKs that may have
implications for their utilization in oligonucleotide delivery
strategies. Obviously, there are other receptor families that
may be of interest. However, many of the same considerations
would apply in those cases. Thus, in designing strategies for
receptor mediated oligonucleotide delivery several important
aspects must be kept in mind. Perhaps most important is the
abundance of the receptor. Although antisense and siRNA
can be very potent, still it is important to have sufficient levels
of receptor expression to be able to deliver significant
amounts of material to the cell interior. Another key aspect is
how actively the receptor internalizes and the degree to which
it recycles. If ligand engagement shunts most of the receptor to
lysosomal degradation, then it will not be possible to maintain
delivery over an extended period whereas an actively re-
cycling receptor will allow this. An essential issue is the
chemistry of the receptor ligand. Will it be possible to couple
the ligand to an oligonucleotide or to a nanocarrier without
loss of ligand affinity or specificity? This can be a challenging
problem as discussed at length elsewhere (Alam et al., 2013).
Finally, one needs to realize that receptors are not just useful
targets for drug delivery, but that they are also key elements
of the cell’s regulatory system. When a ligand-conjugated
oligonucleotide or nanocarrier binds to a cell surface receptor
it will undoubtedly trigger an entire avalanche of signaling
events. This aspect of targeted drug delivery has been largely
ignored (our laboratory is equally guilty here) but needs to be
addressed if receptor mediated delivery of both oligonucleo-
tides and conventional drugs is to progress.
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Cellular Uptake and Intracellular Trafficking of Oligonu-
cleotides and Ligand–Oligonucleotide Conjugates
This section will examine current information on the up-
take and intracellular trafficking of ‘‘free’’ oligonucleotides
and of molecular-scale ligand-oligonucleotide conjugates,
while the behavior of oligonucleotide nanocomplexes is dis-
cussed in another section. The overall biodistribution of var-
ious forms of ‘‘free’’ or ‘‘naked’’ oligonucleotides has been
well studied ( Juliano et al., 1999; Geary, 2009; Bennett and
Swayze, 2010). Whereas uncharged oligonucleotides such as
morpholino and peptide nucleic acid derivatives, as well as
most forms of siRNA, are rapidly excreted via the kidney,
phosphorothioate (PS) oligonucleotides bind more avidly to
plasma proteins and cells and are thus retained in the body for
longer periods. Certain cell types, particularly kidney proxi-
mal tubule cells and liver Kupffer cells, exhibit preferential
uptake both for PS antisense compounds and for siRNA
(Butler et al., 2000; Molitoris et al., 2009). Despite many studies
on biodistribution to tissues, it is only recently that the sub-
cellular trafficking of oligonucleotides and their molecular
scale conjugates has been explored in some depth. For ex-
ample, a study using PS oligonucleotides in transformed he-
patocytes and in murine livers indicated that productive and
non-productive intracellular pathways for delivery coexist,
with the nonproductive pathway probably trafficking to ly-
sosomes (Koller et al., 2011). Other studies in cell culture and
in mouse models, have reported the so-called ‘‘gymnotic’’
uptake of free antisense oligonucleotides modified with
locked nucleic acid moieties (Stein et al., 2010; Zhang et al.,
2011).
Investigators have searched extensively for cell surface
receptors for free oligonucleotides but much of this literature
is controversial. Thus b2 integrins (Benimetskaya et al., 1997)
and scavenger receptors (Butler et al., 1997) have been sug-
gested as possibilities, but some of the evidence is prob-
lematic (Butler et al., 2000). A putative oligonucleotide
transmembrane transporter has been described (Hanss et al.,
2002), but this work has not seen any follow-up. In lower
organisms, a double stranded RNA transport protein termed
SID-1 plays a key role in the cell to cell spread of RNA in-
terference (Winston et al., 2007); however, although there is a
mammalian homolog, reports of its role in siRNA uptake in
mammalian cells have languished (Duxbury et al., 2005;
Tsang et al., 2007; Wolfrum et al., 2007). The clearest example
of receptors for oligonucleotides involves the toll-like re-
ceptor (TLR) family that is essential for the innate immune
response (Robbins et al., 2009; Kawai and Akira, 2011). As a
simplistic summary, TLR9 binds DNA containing CpG mo-
tifs, TLRs7/8 bind single stranded RNA, while TLR3 binds
double stranded RNA. Although TLRs are sometimes found
within endosomes rather than at the cell surface, they
nonetheless seem to be able to assist in the uptake of oligo-
nucleotides by cells.
Oligonucleotide conjugate chemistry
There is a growing literature on oligonucleotides conju-
gated to ligands designed to promote cellular uptake (Watts
et al., 2008; Lonnberg, 2009; Marlin et al., 2010; Singh et al.,
2010; Juliano et al., 2012b; Nguyen and Szoka, 2012). Con-
jugate groups can be incorporated into oligonucleotides by
direct online synthesis on a DNA/RNA synthesizer or by
post-synthetic conjugation to reactive groups incorporated
during automated oligonucleotide synthesis. A recent review
gives a comprehensive overview of the developments in
conjugate chemistry for oligonucleotide synthesis (Singh
et al., 2010) and compares the merits of each approach to
preparing conjugates. Direct online synthesis offers the most
straightforward and versatile option available for preparing
oligonucleotide conjugates. The ability to control the synthesis
allows for the incorporation of single or multiple conjugate
groups at predefined positions anywhere in the sequence. The
major limitation to this method is that the conjugate groups
(with the appropriate protecting groups) must be compatible
with the conditions used for automated oligonucleotide syn-
thesis and deprotection. In cases where the desired conjugate
is incompatible with conditions for automated synthesis,
solution phase post-synthesis conjugation can be employed.
However, solution phase methods may be less efficient
and require more intensive purification. Additionally, func-
tional oligonucleotides can be prepared as aptamer chime-
ras for specific cell receptor mediated targeting (Zhou and
Rossi, 2011).
The copper(1)-catalyzed azide-alkyne cycloaddition is the
most prominent example of a group of reactions named
‘‘click-reactions’’ and has emerged as a highly efficient and
versatile method for preparing conjugates. A recent review
provides an up to date account of the use of click chemistry in
RNA modification and other novel methods for site specific
labeling (Phelps et al., 2012). Alkyne derivatized nucleotide
phosphoramidite bases are now available for solid phase
synthesis that enable single or multiple conjugates to be in-
troduced by click reaction (Yamada et al., 2011). The recent
development of azide functionalized oligonucleotide by using
the 2¢–azido H-phosphonate monomer in chemical synthesis
of RNA (Fauster et al., 2012) and the 5¢-triphosphate of 5-
(3-azidopropyl) uridine that can be incorporated during en-
zymatic synthesis (Rao et al., 2012; Winz et al., 2012) has
further expanded the utility of click chemistry for preparing
conjugates with the versatility of using either azide or alkyne
derivatives of prospective labels.
Lipid conjugates
One important thrust has been the development of con-
jugates with cholesterol or other lipophilic moieties that
promote association with plasma lipoproteins or albumin
and can thus enhance uptake into the liver and elsewhere via
lipoprotein receptors (Krutzfeldt et al., 2005; Wolfrum et al.,
2007; Uno et al., 2011). A recent study showed that double
tailed, saturated lipid conjugated to an oligonucleotide sig-
nificantly improved cellular uptake in a variety of tumor cell
types (Ugarte-Uribe et al., 2013). Impressively, the conjugate
significantly surpassed the cellular uptake achieved by
transfection in HeLa cells. Furthermore, the authors dem-
onstrated that the effects of the conjugate could be dimin-
ished in CR3 receptor knockout cells or through treatment
with soluble fibrinogen thus suggesting another receptor
that can be directly targeted through conjugation. However,
another recent study demonstrates that while lipophilic
moieties, cholesterol or docosanoic acid, improved antisense
oligonucleotide efficacy in silencing Bcl-2, they were sus-
ceptible to the presence of human serum albumin (Felber
et al., 2012).
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Targeted conjugates
Recently there has been a surge of interest in additional re-
ceptor-targeted ligand–oligonucleotide conjugates. For exam-
ple, our laboratory has reported on RGD peptide conjugates of
SSOs or of siRNA that can be delivered to melanoma cells via the
avb3 integrin (Alam et al., 2008, 2010, 2011). We have also ex-
amined bombesin conjugates that are targeted to the BB2 re-
ceptor, a member of the GPCR superfamily that is overexpressed
on prostate cancer cells (Ming et al., 2010). Additionally we have
also targeted oligonucleotides to tumor cells using anisamide, a
high affinity small molecule ligand for the sigma receptor (Na-
kagawa et al., 2010). As mentioned above, targeting TLRs is an
interesting possibility. Thus in one study an unmethylated CpG
oligonucleotide known to bind to TLR9 was chemically conju-
gated to a siRNA, resulting in enhanced uptake by dendritic
cells, macrophages and B-cells, all known to express TLR9, as
well as ‘‘knockdown’’ of endogenous and reporter genes (Kor-
tylewski et al., 2009). This approach has recently been extended
to targeting malignant hematopoietic cells (Zhang et al., 2013).
Carbohydrate moieties can also be useful ligands for target-
ing; some of the earlier work in this area has been reviewed
previously ( Juliano et al., 2012b). More recently, in T-cell lym-
phocytes, the conjugation of aminoglucosamine to a peptide
nucleic acid (PNA) targeting HIV-1 TAR significantly improved
the cellular uptake of the PNA (Das et al., 2012). In addition, the
amino sugar conjugate reduced luciferase activity greater than
naked PNA and scrambled PNA conjugate controls. In another
study, the conjugation of galactose–PEG improved the delivery
of an aptamer targeting the hepatitis C virus (HCV) to mouse
liver tissue while modestly enhancing the ability of the aptamer
to reduce HCV replication (Lee et al., 2013).
Nucleic acid aptamers provide another important tool for
receptor specific delivery of conjugated oligonucleotides. Thus a
pioneering report involved chimeric oligonucleotides comprised
of an aptamer that bound with high affinity to the prostate
specific membrane antigen (PSMA) receptor found in prostate
cancer cells and siRNAs that affected key survival genes such as
Plk1 and Bcl2 (McNamara et al., 2006). The aptamer–siRNA
conjugates were taken up selectively by cells that expressed
PSMA receptor, caused ‘‘knockdown’’ of the target messages in
cell culture, and displayed antitumor activity when locally ad-
ministered. A chemically optimized version of a PMSA apta-
mer-Plk1siRNA chimera displayed antitumor activity against
PMSA expressing tumors when given systemically (Dassie et al.,
2009). In another very interesting study, aptamer-siRNA chi-
meras inhibited tumor growth in vivo using siRNAs directed
against genes involved in nonsense mediate mRNA decay and
thus in immune regulation of tumors (Pastor et al., 2010). Ad-
ditional interesting examples of aptamer–siRNA chimeras have
also been described (Wheeler et al., 2011).
In summary, a number of studies have validated the con-
cept that monomeric ligand–oligonucleotide conjugates can
produce pharmacological effects in both cell culture and in
animals, in the absence of any transfection agents. A further
overview of receptor targeting of oligonucleotides is found in
a recent review (Ming, 2011).
Uptake and Trafficking of Oligonucleotides
Incorporated into Nanocarriers
A widely used strategy for promoting delivery of antisense,
siRNA or other types of oligonucleotides is to incorporate the
nucleic acid into some form of nanoparticle; potentially this
can help to overcome biological barriers, increase cell uptake,
and enhance escape from membrane compartments (Akhtar
and Benter, 2007; Juliano et al., 2009; Whitehead et al., 2009;
Tamura and Nagasaki, 2010). Lipid based nanocarriers have
proven to be very efficacious for the delivery of siRNA to the
liver (Love et al., 2010). Additionally, a variety of polymeric
nanoparticles (Kabanov and Vinogradov, 2009) and other
types of nanocarriers (Petros and DeSimone, 2010) have been
developed for siRNA delivery. Functional delivery of siRNA
to tumors is very challenging; however, targeted lipid based
nanoparticles have displayed substantial promise in this set-
ting (Tseng et al., 2009). A residual concern relates to possible
toxicities associated with the cationic polymers or lipids typ-
ically used to form nanocarriers for oligonucleotide delivery
(Lv et al., 2006; Akhtar, 2010). There is a vast literature on use
of nanoparticles as oligonucleotide delivery agents; here we
will focus on a relatively few reports that have mechanisti-
cally addressed issues of cellular uptake and trafficking.
One study has challenged the conventional view that cat-
ionic lipid carriers functionally deliver siRNA via endocytosis
followed by escape from endosomes (Lu et al., 2009). This
investigation found that only a minor component of the cell-
associated siRNA that contributed to knockdown function,
and that this component probably came from fusion between
the siRNA lipoplexes and the plasma membrane. The study is
employed both chemical inhibitors and molecular reagents
such as dominant negative versions of dynamin and caveolin
to probe uptake pathways. Another interesting report exam-
ined the uptake and trafficking of siRNA associated with
perfluorocarbon nanoparticles (Kaneda et al., 2010) and found
that delivery was via formation of cell–nanoparticle hemifu-
sion complexes followed by lipid raft mediated internaliza-
tion. Our laboratory has compared the uptake and trafficking
pathways of SSOs delivered via cationic lipids or via poly-
ethylenimine, a cationic polymer (Ming et al., 2011). The
study included use of pharmacological inhibitors, colocali-
zation with known markers of internalization, and use of
molecular reagents to modulate uptake and trafficking. In-
terestingly, in agreement with the study on siRNA delivery
discussed above (Lu et al., 2009), functional delivery of anti-
sense associated with lipoplexes was apparently due to fusion
at the plasma membrane, while delivery via polyplexes took
place through an unconventional form of endocytosis.
Gold nanoparticles have also been used as nanocarriers for
oligonucleotide delivery. The so-called ‘‘spherical nucleic ac-
ids (SNAs)’’ are polyanionic structures comprised of densely
packed and highly oriented oligonucleotides that are attached
to the surface of gold nanoparticles via metal-thiol dative
bonds. These nanoparticles can effectively enter more than 50
different cell types without the aid of auxiliary transfection
agents and are able to produce antisense and RNA interfer-
ence activity (Zheng et al., 2012). Mechanism studies have
been followed to elucidate endocytosis pathways of SNAs
(Patel et al., 2010; Choi et al., 2013). The latter study took
advantage of the great resolution of gold particles under
transmission electron microscopy and of molecular tools that
can manipulate endocytotic process. It demonstrated that the
SNAs can bind strongly to class A scavenger receptors and
undergo rapid cellular uptake via a lipid-raft-dependent, ca-
veolae-mediated pathway. Evidence also showed that the
SNAs enter early endosomes. However, it is silent on how
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they traffic after early endosomes and more importantly how
they exit from the endosomal compartment.
Targeting ligands have been engineered into nanoparticle
delivery systems to improve the effectiveness and reduce
potential side effects of therapeutic oligonucleotides (Ming,
2011). Unfortunately, in spite of a substantial number of re-
ports demonstrating superior pharmacological outcomes
than the nontargeted nanoparticles, few mechanistic studies
have been reported to elucidate possible intracellular path-
ways that lead to the greater effectiveness of the targeted
delivery systems. In one recent study, multiple RGD–
morpholino conjugates were linked to a single molecule of
human serum albumin and resulted in integrin-targeted
nanoconjugates (Ming et al., 2013b). The ultra-small (13nm)
nanoparticles showed superior delivery of oligonucleo-
tides into tumor cells and deep penetration throughout 3-
dimensional tumor spheroids (Ming et al., 2013b). The RGD
targeted nanoconjugates undergo dynamin-dependent en-
docytosis (unpublished data) and then traffic to Rab7-positive
late endosomes and Lamp1-positive lysosomes (Ming et al.,
2013b). However, the endosomal release mechanism is still
unresolved.
Recently two articles appeared in the same issue of Nature
Biotechnology that provide the most sophisticated analysis to
date of the cellular uptake and intracellular trafficking of
siRNA associated with nanocarriers (Gilleron et al., 2013;
Sahay et al., 2013). In both cases, the siRNA was incorporated
into (two different) lipid nanoparticles that had shown ex-
cellent efficacy for siRNA delivery in vivo. Both studies used
advanced imaging techniques and chemical and molecular
tools to manipulate uptake and trafficking pathways. One
study suggests an initial phase of uptake via clathrin medi-
ated endocytosis, which then triggers a more robust uptake
via macropinocytosis (Gilleron et al., 2013). This study found
a low level of siRNA escape (*2%) from endosomes via
gradual release rather than a bursting process, and that the
most likely site of escape is from an early endosomal com-
partment. The other study (Sahay et al., 2013) found evidence
for substantial recycling of siRNA to the external medium via
exocytosis from a late endosomal/lysosomal compartment.
The transmembrane glycoprotein NPC1, which is present on
multivesicular late endosomes, is known to be involved in
trafficking of lipids. This study implicated NPC1 in recycling
of the lipid/siRNA complex via a Rab27a-dependent path-
way; for example, they found a substantial improvement in
siRNA potency in NPC1–/– cells or due to knockdown of
Rab27a. The two studies differ in many details but they both
reveal the importance of intracellular processing in the func-
tional delivery of siRNA. Interestingly these studies seem to
counter some of the earlier studies, discussed above, that di-
rect fusion with the plasma membrane accounts for some of
the effects of siRNA associated with lipid carriers.
To summarize, both in the case of molecular scale oligo-
nucleotide conjugates and for oligonucleotides associated
with nanocarriers there is mounting evidence that the
pathways of internalization, trafficking and recycling play
key roles in determining the biological effects of the oligo-
nucleotide. This suggests that it will be very productive to
continue to investigate uptake and trafficking issues for an-
tisense, siRNA and SSOs and that the knowledge gleaned
will be very helpful in therapeutic development of these
types of molecules.
Enhancing the Pharmacological Effects
of Oligonucleotides Using Small Molecules
Oligonucleotides enter and traffic through cells via dy-
namic processes that are regulated by a multiplicity of pro-
teins. Their biological actions involve complex RNA–protein
interactions involving multiprotein entities such as the RNA-
induced silencing complex or the splicesosome. Thus, it
stands to reason that the effects of oligonucleotides can be
modulated using small molecules that affect either trafficking
or the ultimate locus of action. This strategy for improving the
pharmacological effectiveness of oligonucleotides has been
rather neglected until recently. However, a couple of inter-
esting reports on this subject have now emerged.
SSOs that cause exon skipping in the dystrophin gene have
shown promise in treatment of Duchenne muscular dystro-
phy (Cirak et al., 2011). A recent report showed that the small
molecule dantrolene could produce about a 2.5-fold en-
hancement of SSO-mediated exon skipping (Kendall et al.,
2012). Dantrolene acts on the muscle cell ryanodine receptor, a
calcium transporter, and is currently used clinically in treat-
ment of malignant hyperthermia. The mechanism by which
dantrolene enhances splice correction is unclear but presum-
ably may be a calcium-mediated action on the splicing pro-
cess.
Our laboratory has pursued the concept of modulating the
intracellular trafficking of oligonucleotides to attain improved
effects. While it is possible to alter intracellular trafficking
using molecular tools such as activated or dominant negative
Rab proteins, we felt that a better approach would be to seek
small molecules that affect trafficking pathways. In perusing
the literature, we were surprised to learn that very few such
molecules are known (von Kleist and Haucke, 2012). One
report that we found very interesting described a set of small
FIG. 3. Retro-1 enhances small interfering RNA effect. Cells
that stably express firefly luciferase were treated with a
chemically stabilized cholesterol-conjugated siLuc with or
without additional treatment with 100mM Retro-1. Results
are expressed as percentage of luminescence in untreated
control cells. ***p = 0.05. RTKs, receptor tyrosine kinases.
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organic molecules termed ‘‘retro compounds’’ that had
emerged from a high throughput screen for drugs that would
block the action of bacterial toxins (Stechmann et al., 2010). In
a collaborative effort with the group that originated these
compounds, we tested several of them for the ability to en-
hance the actions of oligonucleotides. We were pleased to find
that the agent Retro-1 produced substantial improvements of
the pharmacological effects of both SSOs and classic antisense
oligonucleotides (Ming et al., 2013a). In these studies, the ol-
igonucleotides were used in ‘‘free’’ form, without the inclu-
sion of transfection agents. Through use of confocal
microscopy and markers for specific membrane compart-
ments, we showed that Retro-1 could trigger rapid release of
oligonucleotides from late endosomes, with subsequent ac-
cumulation of SSOs or AS in the nucleus. Retro-1 also pro-
vided a modest enhancement of the action of a SSO in a
xenograft tumor model. In our published studies, we reported
that Retro-1 did not affect the actions of siRNA; however,
those studies used conventional siRNA that was too unstable
to provide a robust effect. Since then we have found that
Retro-1 provides a strong enhancement of the actions of siR-
NA when the oligonucleotide is stabilized by chemical mod-
ification (see Fig. 3). Despite these promising developments,
Retro-1 is not an ideal agent for oligonucleotide pharmacol-
ogy. It is active only at high micromolar concentrations and it
is very lipophilic thus making its in vivo use difficult. For these
reasons, it would seem valuable to undertake additional
screening, as well as using medicinal chemistry approaches,
to seek molecules that enhance oligonucleotide actions, but
with better ‘‘drug-like’’ characteristics.
Summary
A variety of strategies are being pursued to influence the
cellular uptake and subcellular trafficking of oligonucleotide
with the goal of improving pharmacological effects. Most of
the work is still at an early stage and much more information
is needed concerning the intracellular fates of oligonucleo-
tides linked to various ligands or nanocarriers. Additionally,
with a few notable exceptions, most of the work thus far on
mechanisms of uptake and trafficking of oligonucleotides has
been done in simple tissue culture settings, with very limited
in vivo data. Performing mechanistic studies in animals is
challenging but new technologies such as intravital two-
photon microscopy will be very helpful. Additionally, use of
more complex three-dimensional tissue culture models (e.g.,
tumor spheroids) may provide insights into cellular processes
that are absent or altered in simple two-dimensional culture.
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